In an email to CBC News, the federal health body confirmed that it anticipates a limited supply of the vaccine will be available for the upcoming RSV season.
“This has been decades long in the making,” Dr. Isaac Bogoch, an infectious disease specialist with the University Health Network in Toronto, said of the vaccine’s approval.
In a news release issued Friday, GSK said a randomized clinical trial showed the vaccine has an 82 per cent effectiveness at preventing lower respiratory tract disease caused by RSV, compared to seniors who got a placebo.
St. Joseph’s Healthcare Hamilton infectious disease physician Dr. Zain Chagla said available data suggests that people who get the vaccine will be protected for up to two years.
In an email to CBC News, Health Canada said that guidance from the National Advisory Committee on Immunization (NACI) on the use of the vaccine is expected next year.
Experts like Sinha say they also hope the Canadian government considers covering the cost of the vaccine as that can often be a “barrier to access,” especially in more vulnerable populations.
This is the best summary I could come up with:
In an email to CBC News, the federal health body confirmed that it anticipates a limited supply of the vaccine will be available for the upcoming RSV season.
“This has been decades long in the making,” Dr. Isaac Bogoch, an infectious disease specialist with the University Health Network in Toronto, said of the vaccine’s approval.
In a news release issued Friday, GSK said a randomized clinical trial showed the vaccine has an 82 per cent effectiveness at preventing lower respiratory tract disease caused by RSV, compared to seniors who got a placebo.
St. Joseph’s Healthcare Hamilton infectious disease physician Dr. Zain Chagla said available data suggests that people who get the vaccine will be protected for up to two years.
In an email to CBC News, Health Canada said that guidance from the National Advisory Committee on Immunization (NACI) on the use of the vaccine is expected next year.
Experts like Sinha say they also hope the Canadian government considers covering the cost of the vaccine as that can often be a “barrier to access,” especially in more vulnerable populations.
I’m a bot and I’m open source!